Formiga Pérez, FrancescChivite, DavidNuñez, JulioMoreno García, Ma. CarmenManzano, LuisArévalo-Lorido, José CarlosCerqueiro, Jose ManuelGarcía Campos, ÁlvaroTrullàs, Joan CarlesMontero Pérez-Barquero, Manuel2022-11-142022-11-142022-10-010870-2551https://hdl.handle.net/2445/190795Introduction: Beta-adrenergic receptor blockers (beta-blockers) are frequently used for patients with heart failure (HF) with preserved ejection fraction (HFpEF), although evidence-based recommendations for this indication are still lacking. Our goal was to assess which clinical factors are associated with the prescription of beta-blockers in patients discharged after an episode of HFpEF decompensation, and the clinical outcomes of these patients. Methods: We assessed 1078 patients with HFpEF and in sinus rhythm who had experienced an acute HF episode to explore whether prescription of beta-blockers on discharge was associated with one-year all-cause mortality or the composite endpoint of one-year all-cause death or HF readmission. We also examined the clinical factors associated with beta-blocker discharge prescription for such patients. Results: At discharge, 531 (49.3%) patients were on beta-blocker therapy. Patients on beta-blockers more often had a prior diagnosis of hypertension and more comorbidity (including ischemic heart disease) and a better functional status, but less often a prior diagnosis of chronic obstructive pulmonary disease. These patients had a lower heart rate on admission and more often used angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors and loop diuretics. One year after the index admission, 161 patients (15%) had died and 314 (29%) had experienced the composite endpoint. After multivariate adjustment, beta-blocker prescription was not associated with either all-cause mortality (HR=0.83 [95% CI 0.61-1.13]; p=0.236) or the composite endpoint (HR=0.98 [95% CI 0.79-1.23]; p=0.882). Conclusion: In patients with HFpEF in sinus rhythm, beta-blocker use was not related to one-year mortality or mortality plus HF readmission.9 p.application/pdfengcc-by-nc-nd (c) Sociedade Portuguesa de Cardiologia , 2022https://creativecommons.org/licenses/by-nc-nd/4.0/AngiotensinesArrítmiaMortalitatInsuficiència cardíacaAngiotensinsArrhythmiaMortalityHeart failureinfo:eu-repo/semantics/article7255892022-11-14info:eu-repo/semantics/openAccess36207068